Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.


Russell, FM; Licciardi, PV; Balloch, A; Biaukula, V; Tikoduadua, L; Carapetis, JR; Nelson, J; Jenney, AW; Waqatakirewa, L; Colquhoun, S; Cheung, YB; Tang, ML; Mulholland, EK; (2010) Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine, 28 (18). pp. 3086-94. ISSN 0264-410X DOI: 10.1016/j.vaccine.2010.02.065

Full text not available from this repository. (Request a copy)

Abstract

Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p<0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
PubMed ID: 20199764
Web of Science ID: 277064500004
URI: http://researchonline.lshtm.ac.uk/id/eprint/1095678

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
263Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item